stocks logo

IKT

Inhibikase Therapeutics Inc
$
1.790
+0.02(1.130%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.800
Open
1.790
VWAP
--
Vol
57.54K
Mkt Cap
131.58M
Low
1.740
Amount
--
EV/EBITDA(TTM)
--
Total Shares
7.22M
EV
38.40M
EV/OCF(TTM)
--
P/S(TTM)
--
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Show More
1 Analyst Rating
up Image
346.93% Upside
Wall Street analysts forecast IKT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IKT is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
up Image
346.93% Upside
Current: 1.790
sliders
Low
8.00
Averages
8.00
High
8.00
HC Wainwright & Co.
Edward White
Hold
Reiterates
n/a
2025-03-28
Reason
HC Wainwright & Co.
Edward White
Strong Buy
to
Hold
Downgrades
n/a
2025-02-12
Reason
Jefferies
Dennis Ding
Strong Buy
Initiates
$8
2024-11-08
Reason
Jefferies initiated coverage of Inhibikase Therapeutics with a Buy rating and $8 price target. The stock looks inexpensive as its novel imatinib oral pro-drug IkT-001Pro will enter Phase 2B for PAH, with an added free Parkinson's call option for oral risvodetinib, where expectations are super low, the analyst tells investors in a research note.
HC Wainwright & Co.
Edward White
Strong Buy
Maintains
$15 → $5
2024-10-14
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Maintains
$23 → $15
2024-08-16
Reason

Valuation Metrics

The current forward P/E ratio for Inhibikase Therapeutics Inc (IKT.O) is -4.66, compared to its 5-year average forward P/E of -3.38. For a more detailed relative valuation and DCF analysis to assess Inhibikase Therapeutics Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.38
Current PE
-4.66
Overvalued PE
-0.21
Undervalued PE
-6.55

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
29.05
Current PS
0.00
Overvalued PS
65.56
Undervalued PS
-7.46

Financials

Annual
Quarterly
FY2025Q1
0.00
Total Revenue
FY2025Q1
YoY :
+229.60%
-15.76M
Operating Profit
FY2025Q1
YoY :
+194.19%
-13.68M
Net Income after Tax
FY2025Q1
YoY :
-79.45%
-0.15
EPS - Diluted
FY2025Q1
YoY :
+17.81%
-4.56M
Free Cash Flow
FY2025Q1
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q1
N/A
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
3
2.7M
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
580.6K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
5
30.4M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

IKT News & Events

Events Timeline

2025-04-14 (ET)
2025-04-14
08:14:43
Inhibikase Therapeutics announces appointment of McIntyre as CFO
select
2025-02-24 (ET)
2025-02-24
08:14:17
Inhibikase appoints Chris Cabell as president, head of R&D, John Adams as CSO
select
2025-02-18 (ET)
2025-02-18
08:21:24
Inhibikase Therapeutics appoints Mark Iwicki as CEO
select
Sign Up For More Events

News

9.5
05-14Newsfilter
Inhibikase Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Activity
7.0
05-05PRnewswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)
5.0
04-14Newsfilter
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
Sign Up For More News

FAQ

arrow icon

What is Inhibikase Therapeutics Inc (IKT) stock price today?

The current price of IKT is 1.79 USD — it has increased 1.13 % in the last trading day.

arrow icon

What is Inhibikase Therapeutics Inc (IKT)'s business?

arrow icon

What is the price predicton of IKT Stock?

arrow icon

What is Inhibikase Therapeutics Inc (IKT)'s revenue for the last quarter?

arrow icon

What is Inhibikase Therapeutics Inc (IKT)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Inhibikase Therapeutics Inc (IKT)'s fundamentals?

arrow icon

How many employees does Inhibikase Therapeutics Inc (IKT). have?

arrow icon

What is Inhibikase Therapeutics Inc (IKT) market cap?